2-(amino-substituted)-4-phenyl pyrimidines useful for treating inflammatory diseases
申请人:Millennium Pharmaceuticals, Inc.
公开号:EP2123647A1
公开(公告)日:2009-11-25
A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:
一种具有式 I 的杂环抑制剂,其变量在此定义,可用于治疗 PKC-theta 同工酶在其中起作用的炎症和其他生理疾病:
CXCR4 inhibitors and uses thereof
申请人:X4 Pharmaceuticals, Inc.
公开号:US11332470B2
公开(公告)日:2022-05-17
The present invention provides compounds, compositions thereof, and methods of using the same.
本发明提供了化合物、其组合物以及使用方法。
CXCR4 INHIBITORS AND USES THEREOF
申请人:X4 Pharmaceuticals, Inc.
公开号:US20190322671A1
公开(公告)日:2019-10-24
The present invention provides compounds, compositions thereof, and methods of using the same.
2,2,6- and 2,3,5-Trimethylpiperazines as monocyclic analogues of the μ-opioid agonist 3,8-diazabicyclo[3.2.1]octanes: Synthesis, modeling, and activity
A series of trimethylpiperazine derivatives, structurally related to the μ-agonist 3-cinnamyl-8-propionyl-3,8-diazabicyclo[3.2.1]octane, have been synthesized and tested in binding studies, using 3H-DAMGO as μ-selective ligand. Their different affinity towards μ-opioid receptors has been interpreted on the basis of a molecular modeling study performed through molecular mechanics calculations and high
使用3 H-DAMGO作为μ-选择性配体。在通过分子力学计算和高场1 H MNR光谱进行的分子建模研究的基础上,已经解释了它们对μ阿片受体的不同亲和力。